Patents by Inventor Priyesh Jain

Priyesh Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10828398
    Abstract: Functionalized zwitterionic and mixed charge polymers and copolymers, methods for making the polymers and copolymers, hydrogels prepared from the functionalized zwitterionic and mixed charge polymers and copolymers, methods for making and using the hydrogels, and zwitterionic and mixed charge polymers and copolymers for administration for therapeutic agents.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: November 10, 2020
    Assignee: University of Washington
    Inventors: Shaoyi Jiang, Tao Bai, Harihara Subramanian Sundaram, Andrew William Sinclair, Jean-René Ella-Menye, Priyesh Jain
  • Publication number: 20200289712
    Abstract: Functionalized zwitterionic and mixed charge polymers and copolymers, methods for making the polymers and copolymers, hydrogels prepared from the functionalized zwitterionic and mixed charge polymers and copolymers, methods for making and using the hydrogels, and zwitterionic and mixed charge polymers and copolymers for administration for therapeutic agents.
    Type: Application
    Filed: April 29, 2019
    Publication date: September 17, 2020
    Applicant: University of Washington
    Inventors: Shaoyi Jiang, Tao Bai, Harihara Subramanian Sundaram, Andrew William Sinclair, Jean-René Ella-Menye, Priyesh Jain
  • Publication number: 20200253192
    Abstract: Zwitterionic microgels, zwitterionic microgel assemblies, their formulations and methods for their use.
    Type: Application
    Filed: July 20, 2017
    Publication date: August 13, 2020
    Applicant: University of Washington
    Inventors: Shaoyi Jiang, Andrew Sinclair, Mary Elizabeth O'Kelly, Tao Bai, Priyesh Jain
  • Publication number: 20200123294
    Abstract: N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 23, 2020
    Applicant: University of Washington
    Inventors: Shaoyi Jiang, Priyesh Jain, Jinrong Ma
  • Patent number: 10272180
    Abstract: Functionalized zwitterionic and mixed charge polymers and copolymers, methods for making the polymers and copolymers, hydrogels prepared from the functionalized zwitterionic and mixed charge polymers and copolymers, methods for making and using the hydrogels, and zwitterionic and mixed charge polymers and copolymers for administration for therapeutic agents.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: April 30, 2019
    Assignee: University of Washington
    Inventors: Shaoyi Jiang, Tao Bai, Harihara Subramanian Sundaram, Andrew William Sinclair, Jean-René Ella-Menye, Priyesh Jain
  • Publication number: 20190002625
    Abstract: Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions.
    Type: Application
    Filed: June 2, 2016
    Publication date: January 3, 2019
    Applicant: University of Washington
    Inventors: Shaoyi Jiang, Tao Bai, Jean-René Ella-Menye, Hsiang-Chieh Hung, Priyesh Jain, Andrew Sinclair, Harihara Subramanian Sundaram, Yang Li, Peng Zhang
  • Publication number: 20180362583
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
  • Patent number: 10059740
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 28, 2018
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA
    Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
  • Publication number: 20170266350
    Abstract: Functionalized zwitterionic and mixed charge polymers and copolymers, methods for making the polymers and copolymers, hydrogels prepared from the functionalized zwitterionic and mixed charge polymers and copolymers, methods for making and using the hydrogels, and zwitterionic and mixed charge polymers and copolymers for administration for therapeutic agents.
    Type: Application
    Filed: September 9, 2015
    Publication date: September 21, 2017
    Applicant: University of Washington
    Inventors: Shaoyi Jiang, Tao Bai, Harihara Subramanian Sundaram, Andrew William Sinclair, Jean-René Ella-Menye, Priyesh Jain
  • Publication number: 20160257712
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Application
    Filed: May 26, 2016
    Publication date: September 8, 2016
    Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, PRIYESH JAIN, WILLIAM S. DALTON
  • Publication number: 20150105328
    Abstract: The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: MARK MCLAUGHLIN, PRIYESH JAIN
  • Publication number: 20150071918
    Abstract: The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in the treatment of cancers as monotherapies or in combination with other anti-cancer agents, such as proteasome inhibitors, inhibitors of autophagy, alkylating agents, MEK inhibitors, FAK/PYK2 inhibitors, and EGFR inhibitors. The invention further concerns a method of predicting the binding of a cyclic or linear HYD1 peptide to a cancer cell by assessing overexpression of biomarkers such as CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59.
    Type: Application
    Filed: May 9, 2013
    Publication date: March 12, 2015
    Inventors: Mark McLaughlin, Lori Hazlehurst, Priyesh Jain, Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair
  • Publication number: 20150017259
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Application
    Filed: August 21, 2014
    Publication date: January 15, 2015
    Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, PRIYESH JAIN, WILLIAM S. DALTON
  • Patent number: 8853149
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: October 7, 2014
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
  • Publication number: 20130065837
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Application
    Filed: March 21, 2011
    Publication date: March 14, 2013
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Lori Hazlehurst, Mark Mclaughlin, Priyesh Jain, William S. Dalton